There is a COVID-19 vaccine that American media is not talking about.

Pre-Order on iTunes now. 30% discount!

18 Karat Reggae Gold 2021 : ONENESS
18 Karat Reggae Gold 2021 : ONENESS
India COVID Vaccine
India COVID Vaccine

For the most part Americans only know what the American media wants them to know. Most Americans, even the ones who invest in stocks do no know that India also have a vaccine that is currently being administered to the people of India.

The Indian government is so confident in the vaccine that they gave it emergency approval even before the Phase-III testing is stil

On Tuesday, Ocugen (OCGN) announced it had finalized its deal with India-based Bharat Biotech. The two will work together on COVAXIN, Bharat’s Covid-19 vaccine, for the U.S. market.

Ocugen will take on all aspects of U.S. based responsibilities, including clinical development, regulatory approval, and commercialization. If the vaccine is granted an EUA, Bharat anticipates supplying the U.S. market’s initial COVAXIN doses.

Bharat, in return, will be eligible for 55% of U.S. sales’ profits, with Ocugen retaining the other 45%.

Related Article:   Judge orders man to get vaccinated or go to prison.

Ocugen gets a head start, as COVAXIN has already been granted emergency use authorization in India. It is also currently in a Phase 3 study with 25,800 subjects enrolled.

H.C. Wainwright analyst Swayampakula Ramakanth says the vaccine has qualities which set it apart from the competition.

“Compared to COVID-19 vaccines currently authorized under EUA, COVAXIN could induce more broad immunity targeting multiple viral proteins, potentially resulting in better protection against emerging mutant viruses, such as the UK and South African variants,” the 5-star analyst noted. “Additionally, COVAXIN only requires a standard vaccine storage temperature, compared to the more stringent storage requirements for the mRNA vaccines.”

The vaccine, therefore, “could strengthen the arsenal to fight against the pandemic.”

Related Article:   Blacks love complaining and do not want to be successful, according to Jared Kushner.

Ocugen is already in talks with the FDA and the Biomedical Advanced Research and Development Authority (BARDA) to m

ap out the path forward to “a successful EUA.”

Given the dire need for Covid-19 vaccines, Ramakanth believes that should the Indian Phase 3 study display more than a 50% success rate, there’s a possibility the FDA could make an “unprecedented move” and grant COVAXIN EUA status.

“Therefore,” the analyst summed up, “We believe COVAXIN has the potential to deliver significant upside in the next 6-12 months.”

As a result, Ramakanth upgraded Ocugen’s rating from Neutral (i.e. Hold) to Buy with a $4.5 price target. The implication for investors? Upside of 60% for the coming year.

Comments

comments

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 169,171 other subscribers

Be the first to comment

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.